Compositions and methods for treating leukemia

Patent metadata

Field	Value
Publication number	US-9815849-B2
Application number	US-201313934843-A
Country	US
Kind code	B2
Filing date	Jul 3, 2013
Priority date	May 14, 2010
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The invention provides compositions, methods, and kits for the treatment of acute myeloid leukemia in a subject.

First claim

What is claimed is:

1. A method for treating a leukemia or related disorder in a subject, the method comprising administering to the subject an effective amount of at least one agent that inhibits Brd4 or a derivative thereof represented by the following structural formulas

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the leukemia is acute myeloid leukemia (AML), Chronic Lymphocydic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Eosinophilic Leukemia, Hairy Cell Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Myeloproliferative disorders or Myelodysplastic syndromes.

3. A method for reducing the growth, proliferation or survival of a leukemic cell, the method comprising contacting the cell with an effective amount of at least one agent that inhibits Brd4 or a derivative thereof,
represented by the following structural formulas

or a pharmaceutically acceptable salt thereof,
thereby reducing the growth, proliferation or survival of a leukemic cell.

4. A method of inducing cell death or terminal differentiation in a leukemic cell, the method comprising contacting the cell with an effective amount of at least one agent that inhibits Brd4 or a derivative thereof, represented by the following structural formulas

or a pharmaceutically acceptable salt thereof,
thereby inducing cell death or terminal differentiation in the leukemic cell.

5. The method of claim 3 or 4 , wherein the cell is in a subject.

6. The method of claim 3 or 4 , wherein the cell is derived from an acute myeloid leukemia (AML), Chronic Lymphocydic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Eosinophilic Leukemia, Hairy Cell Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Myelodysplasia or Myeloproliferative Disorders.

7. A method of treating acute myeloid leukemia in a subject, the method comprising administering to a subject in need thereof an effective amount of at least one agent that inhibits Brd4, represented by the following structural formulas

or a pharmaceutically acceptable salt thereof,
thereby treating acute myeloid leukemia in a subject.

8. The method of claim 7 , wherein the subject is a mammal.

9. The method of claim 8 , wherein the subject is a human patient.

10. The method of claim 9 , wherein the human patient is an adult.

11. The method of claim 9 , wherein the human patient is a child.

12. The method of claim 7 , wherein the method reduces the growth, proliferation or survival of a leukemic cell in a subject.

13. A method of any one of claim 1 , 3 , 4 or 7 , wherein the at least one agent is represented by any one of the following structural formulas:

Assignees

• Dana Farber Cancer Inst Inc
• Cold Spring Harbor Laboratory

Inventors

• Bradner James Elliott
• Zuber Johannes
• Shi Junwei
• Vakoc Christopher R
• Lowe Scott W
• Mitsiades Constantine S

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/5517

  condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title